Prevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients

Johanna G. Mitterreiter1,2, Maarten J. Titulaer3, Gijsbert P. van Nierop3,2, Jeroen J. A. van Kampen2, Georgina I. Aron2, Albert D. M. E. Osterhaus1,2, Georges M. G. M. Verjans2,1, Werner J. D. Ouwendijk2*

1 Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany, 2 Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands, 3 Department of Neurology, Erasmus MC, Rotterdam, the Netherlands

*w.ouwendijk@erasmusmc.nl

Abstract

Herpes simplex encephalitis (HSE) is a life-threatening complication of herpes simplex virus (HSV) infection. Acyclovir (ACV) is the antiviral treatment of choice, but may lead to emergence of ACV-resistant (ACVR) HSV due to mutations in the viral UL23 gene encoding for the ACV-targeted thymidine kinase (TK) protein. Here, we determined the prevalence of intrathecal ACVR-associated HSV TK mutations in HSE patients and compared TK genotypes of sequential HSV isolates in paired cerebrospinal fluid (CSF) and blister fluid of mucosal HSV lesions. Clinical samples were obtained from 12 HSE patients, encompassing 4 HSV type 1 (HSV-1) and 8 HSV-2 encephalitis patients. HSV DNA load was determined by real-time PCR and complete HSV TK gene sequences were obtained by nested PCR followed by Sanger sequencing. All HSV-1 HSE patients contained viral TK mutations encompassing 30 unique nucleotide and 13 distinct amino acid mutations. By contrast, a total of 5 unique nucleotide and 4 distinct amino acid changes were detected in 7 of 8 HSV-2 patients. Detected mutations were identified as natural polymorphisms located in non-conserved HSV TK gene regions. ACV therapy did not induce the emergence of ACVR-associated HSV TK mutations in consecutive CSF and mucocutaneous samples of 5 individual patients. Phenotypic susceptibility analysis of these mucocutaneous HSV isolates demonstrated ACV-sensitive virus in 2 HSV-1 HSE patients, whereas in two HSV-2 HSE patients ACVR virus was detected in the absence of known ACVR-associated TK mutations. In conclusion, we did not detect intrathecal ACVR-associated TK mutations in HSV isolates obtained from 12 HSE patients.

Introduction

Herpes simplex encephalitis (HSE) is a rare life-threatening complication of infection with herpes simplex virus type 1 (HSV-1) and HSV-2. HSE affects 1 in 250,000 to 500,000 persons per year in the USA and comprises about one-fifth of all encephalitis cases in the UK [1,2]. HSV-1 causes 90% of HSE cases in immunocompetent adults, whereas HSV-2-associated HSE is more
Acyclovir Resistance in HSV Encephalitis Patients

common in neonates and immunocompromised individuals [2,3]. Prompt diagnosis, based on magnetic resonance imaging of the brain and detection of HSV DNA in cerebrospinal fluid (CSF) by PCR, and preemptive administration of antiviral drugs are pivotal to reduce HSE-induced morbidity and mortality [2–4]. Mortality from HSE is about 70% in untreated patients, which is reduced to 11% to 19% when immediate antiviral therapy is provided [1,5]. Nevertheless, approximately 12% to 60% of treated HSE patients develop neurological sequelae [1,5].

Treatment of choice is intravenous administration of the antiviral agent acyclovir (ACV), a highly selective drug for human alphaherpesviruses with limited side effects [6,7]. ACV is a prodrug converted by the viral thymidine kinase (TK) protein to ACV-monophosphate, which is subsequently converted by cellular kinases to the active compound ACV-triphosphate that inhibits HSV DNA replication [8]. ACV resistant (ACVR) HSV is found in less than 1% of immunocompetent, but more frequently in immunocompromised individuals (4% to 30%) and in infected immunoprivileged organs including the cornea [8–11]. Over 95% of ACVR HSV are caused by mutations in the viral UL23 gene encoding the ACV-targeted TK protein, while mutations in the viral UL30 DNA polymerase gene account for the remaining 5% [12]. Few studies reported on ACV treatment refractory HSE cases due to infection with ACVR HSV, but the overall prevalence of intrathecal ACVR HSV in a clinically unbiased cohort of patients with either HSV-1 or HSV-2-induced HSE has not been described [13–16]. Furthermore, the highly polymorphic nature of the HSV-1 UL23 TK gene, and to a lesser account its HSV-2 counterpart, facilitates genetic differentiation of HSV isolates [10,17,18].

The aim of this study was twofold. First, to determine the prevalence of intrathecal ACVR HSV in a cohort of 4 HSV-1 and 8 HSV-2 HSE patients. Second, to compare the HSV TK genotype variation of sequential CSF and/or blister fluid samples (BLS) obtained from the same patient during the course of disease.

Materials and Methods

Clinical specimens

Surplus CSF samples of suspected HSE patients, obtained for diagnostic purposes at the Erasmus Medical Center (Rotterdam, the Netherlands), were collected between 2001 to 2012. A total of 15 CSF samples from 12 HSE patients were included: HSV-1 (n = 4) and HSV-2 (n = 8) (Table 1). Additionally, paired BLS from mucocutaneous lesions of two HSV-1 (patients #3 and #4) and two HSV-2 HSE patients (patients #10 and #11) were obtained. According to our institutional “Opt-Out” system, which is defined by the National “Code of Good Conduct” (Dutch: Code Goed Gebruik, May 2011) [19], surplus clinical materials are made available for research purposes if the patient has not objected. Specifically, patients/donors or caretakers that object are registered and their specimens are excluded from future research. Accordingly, the current study used only surplus clinical samples from HSE patients that did not object use of their surplus clinical samples for future research purposes. The study protocol was approved by the medical ethical committee of the Erasmus MC (MEC-2012-226) and informed consent was waived. The study was performed according to the tenets of the Helsinki declaration.

DNA extraction and quantitative real-time PCR

DNA was extracted from CSF and BLS samples using the QIAamp DNA Mini Kit (Qiagen) according to manufacturer’s instructions. Quantitative PCR (qPCR) for HSV was performed using an ABI Prism 7500 Real-Time PCR System and TaqMan Universal PCR Master Mix (Life Technologies) with primers and probes specific for HSV-1 and HSV-2 as described before [20]. Electron microscopy quantified high-titer HSV stocks (Advanced Biotechnologies
Incorporated) were used for standardization of qPCR assays [20]. The lower limit of detection was 50 HSV genome equivalent copies per mL.

**HSV TK gene sequencing**

The entire HSV-1 and HSV-2 TK genes (both 1,131 bp long) were amplified from DNA extracted from clinical specimens by nested PCR using PfuUltra II Fusion HS DNA Polymerase (Stratagene), 5% dimethyl sulfoxide (Sigma-Aldrich) and the following primers at the indicated concentrations: HSV-1 external forward 5'-GCGGTCCCAGGTCCACTTC-3' (1.2 μM), HSV-1 external reverse 5'-cacccgtgcgttttattctgtc-3' (1.2 μM), HSV-1 nested forward 5'-atcttgcttgctgaaactcc-3' (0.4 μM), HSV-1 nested reverse 5'-ggttccttccggtattgtctcc-3' (0.4 μM), HSV-2 external forward 5'-gtcagcagcgttccacaaatcc-3' (0.6 μM), HSV-2 external reverse 5'-ggggtggggtgagggtaaaag-3' (0.6 μM), HSV-2 nested forward 5'-actctgg tgccgtaaactcc-3' (0.4 μM), HSV-2 nested reverse 5'-ggtccctcvcctggtattgtcc-3' (0.4 μM), HSV-2 external forward 5'-gctcagcagcgttccacaatcc-3' (0.6 μM), HSV-2 external reverse 5'-ggggtggggtgagggtaaaag-3' (0.6 μM), HSV-2 nested forward 5'-cggtaaactccgcctcctc-3' (0.4 μM) and HSV-2 nested reverse 5'-cccccgcgcttatggacac-3' (0.4 μM) (all from Eurogentec) [10]. First round amplification conditions included denaturation for 2 min at 95°C, followed by 40 cycles 30 s at 95°C, 25 s at 62°C, 40 s at 72°C and a final elongation of 3 min at 72°C. Nested PCR was performed, using 1 μl of the first PCR reaction, for 35 cycles using identical conditions. The resulting TK amplicons were purified from agarose gel using the MiniElute Gel Extraction Kit (Qiagen) and sequenced on the ABI Prism 3130 XL Genetic Analyzer with the BigDye v3.1 Cycle Sequencing Kit (both Applied Biosciences), the above-mentioned nested primers, and the following additional internal primers at the indicated concentrations: HSV-1 internal forward 5'-CGCCCAGATAACAATGGGC-3' (1 μM), HSV-1 internal reverse 5'-CCCATAACGCGG

| Patient | Virus | Age, Sex | Immune status | Time onset-first CSF | Time onset-AV therapy | AV therapy (duration in days) | Follow-up (months) | Clinical outcome at end of follow-up |
|---------|-------|----------|---------------|----------------------|-----------------------|-----------------------------|-------------------|-----------------------------------|
| 1       | HSV-1 | 51, F    | -             | 11 months            | None                  | None                        | 142               | Moderate disability              |
| 2       | HSV-1 | 35, M    | +             | 4 days               | 4 days                | ACV iv (14); GCV iv (28)    | 18                | Complete recovery                |
| 3       | HSV-1 | 64, F    | +             | 3 days               | 5 days                | ACV iv (14); ACV oral (7)   | 1                 | Complete recovery                |
| 4       | HSV-1 | 47, M    | -             | 14 days              | 10 days               | ACV iv (±14–21)             | 114               | Severe disability               |
| 5       | HSV-2 | 59, M    | -             | 21 days              | 22 days               | ACV iv (10)                 | 24                | Complete recovery                |
| 6       | HSV-2 | 36, F    | +             | 4 days               | 4 days                | ACV iv (±14–21)             | Unknown           | Unknown                          |
| 7       | HSV-2 | 19, F    | +             | 1 day                | 3 days                | ValGCV oral (12)            | 7                 | Complete recovery                |
| 8       | HSV-2 | 49, F    | +             | 1 day                | 1 day                 | ValACV oral (14)            | 38                | Moderate disability             |
| 9       | HSV-2 | 61, M    | -             | 10 days              | 10 days               | ACV iv (28); ValACV oral (21) | 18               | Good recovery                    |
| 10      | HSV-2 | 28, M    | -             | 5 days               | 5 days                | ACV iv (14)                 | 108               | Complete recovery                |
| 11      | HSV-2 | 35, M    | -             | ± 2 months           | 14 days               | ACV iv (2); none (32); ValACV oral (39) | 3                            | Good recovery        |
| 12      | HSV-2 | 61, M    | -             | 8 days               | 3 days                | ACV iv (19)                 | 3                 | Good recovery                    |

Table 1. Demographics and clinical characteristics of herpes simplex encephalitis patients.

**Notes:**

a Causative virus.

b Age in years. F: female; M: male.

c +: immunocompetent; --: immunocompromised.

d Time interval between the onset of clinical symptoms and time of (first) cerebrospinal fluid (CSF) sample.

e Time interval between the onset of clinical symptoms and the onset of antiviral (AV) therapy.

f Successive antiviral therapies and routes of administration are indicated. ACV: acyclovir; GCV: ganciclovir; ValACV: valacyclovir; ValGCV: valganciclovir; iv: intravenous.

g Complete recovery: no adverse events; other outcome criteria classified according to Glasgow outcome scale [22].

doi:10.1371/journal.pone.0155531.t001

Incorporated) were used for standardization of qPCR assays [20]. The lower limit of detection was 50 HSV genome equivalent copies per mL.
CGAATCG-3’ (1 μM), HSV-2 internal forward 5’-accaggtctgcgcggcgcccgtc-3’ (1 μM) and HSV-2 internal reverse 5’-tatgcctccctctgtgctaccc-3’(1 μM), as described [10,21]. TK sequences were aligned to consensus TK sequences of the HSV-1 reference strain 17 (GenBank accession number: JN555585.1) and HSV-2 reference strain HG52 (NCBI accession number: NC_001798.1) using Lasergene 10.1 (DNASTAR). Obtained HSV-1 and HSV-2 TK sequences were deposited in GenBank under the accession numbers KT266758–KT266777.

Phenotypic ACV susceptibility of HSV isolates

Phenotypic ACV susceptibilities of herpes simplex virus isolates were determined by plaque reduction assay according to the Clinical and Laboratory Standards Institute’s guidelines. In brief, confluent monolayers of Vero cells cultured in 12-well plates were infected with 50–100 plaque forming units HSV per well for 75 min at 36.5°C in a CO2 incubator. Inoculum was removed and EMEM containing 0.8% agarose (both Lonza) and 0–64 mg/mL ACV (GlaxoSmithKline) was added. Plates were incubated at 36.5°C with 5% CO2 for 72 hours, fixed using 10% formalin and stained with crystal violet. Plaques were counted using a light microscope. HSV reference strains HSV-1 F and HSV-2 HG52 were included as ACV-sensitive controls. GraphPad Prism 5 was used to calculate the half maximum (50%) inhibitory concentrations (IC50) of ACV from the dose response curves using the log(inhibitor) versus normalized response with a variable Hill slope. Experiments were performed in duplicate and three independent experiments were performed. HSV isolates were considered ACV^R if the mean IC50 was equal or greater than five times the IC50 value of the sensitive control HSV-1 or HSV-2 strains.

Results

Demographics and clinical characteristics of HSE patients

Fifteen CSF samples were obtained from 12 HSE patients comprising 4 HSV-1 and 8 HSV-2 HSE cases (Table 1). Five of 12 (42%) of patients were female, the overall median age at time of the first CSF sample was 48 years (range: 19–64 years) and 7 of 12 patients (58%) were immunocompromised. Age, gender and immune status distribution were comparable between HSV-1 and HSV-2 HSE patients. Median time interval between onset of disease and first CSF sample was 6.5 days (range: 1 day–11 months). Eleven of 12 patients (92%) received antiviral therapy, starting at a median time interval of 5 days (range: 1–22 days) after onset of disease symptoms. Patient #1 did not receive antiviral therapy because she was initially suspected of and treated for tuberculous meningoencephalitis; HSV-1 DNA was detected in CSF at 11 months after onset of neurological disease. The median follow-up was 18 months (range: 1 month–11 years); one patient was lost to follow-up. Five of 11 patients (45%) showed complete recovery, 3 of 11 patients (27%) showed good recovery, 2 of 11 (18%) patients showed moderate disabilities and 1 patient developed severe disabilities according to the Glasgow outcome scale [22].

Prevalence of ACV^R HSV in CSF from HSE patients

To determine the prevalence of intrathecal ACV^R HSV in the cohort of clinically unbiased HSV-1 (n = 4) and HSV-2 (n = 8) HSE patients, DNA was isolated from surplus CSF and subsequently used to amplify the complete viral TK gene by nested PCR followed by Sanger sequencing. Median HSV-1 and HSV-2 DNA loads in the primary CSF samples of the HSE patients were 3.7 x 10^4 copies/mL (range <50–1.3 x 10^6 copies/mL) and 1.8 x 10^4 copies/mL (range 5.0x10^2–2.2x10^5 copies/mL), respectively (Table 2). HSV-1 and HSV-2 TK sequences were obtained from all CSF samples analyzed, irrespective of viral DNA load. Among HSV-1
HSE patients, all CSF samples had viral TK mutations comprising 30 unique nucleotide and 13 distinct amino acid substitutions compared to HSV-1 reference strain 17 (Table 2). By contrast, TK sequences in 7 of 8 (88%) CSF samples from HSV-2 HSE patients contained mutations, encompassing only 5 unique nucleotide and 4 distinct amino acid substitutions compared to HSV-2 reference strain HG52.

To predict the impact of the detected mutations on TK function, we determined their location with respect to highly conserved and functional domains of HSV-1 and HSV-2 TK (Fig 1). Except for the D286E mutation in HSV-1 TK protein of patient #4, all amino acid substitutions were located in non-conserved TK domains. All HSV-2 TK and 11 of 13 (85%) HSV-1 TK amino acid substitutions were previously defined as natural polymorphisms resulting in an ACV sensitive (ACVS) HSV phenotype [10–12, 23–27]. The HSV-1 TK isolate from patient #4 contained the R41H mutation, previously described as natural polymorphism but also as ACVR-associated mutation [10,12,28–30]. One new non-synonymous mutation (C689T) was identified in CSF of HSV-1 HSE patient #2 resulting in the exchange of the nonpolar neutral amino acid alanine at position 230 with a similar nonpolar neutral amino acid valine (Table 2). Collectively, the data indicate that the prevalence of intrathecal ACVR-associated TK mutations in HSV-1 and HSV-2 in HSE patients is low.

Genetic characterization of HSV TK in sequential virus isolates of individual HSE patients

Besides the causative role of TK mutations in the viral ACV susceptibility phenotype, the variability of the TK provides insight into the clonal composition of an HSV-1 isolate [10,17,18]. From 4 HSE patients multiple CSF, and/or BLS from oral HSV-1 or anal HSV-2 mucosal lesions were obtained during the same HSE episode (patients #3, #4, #9, and #11). Additionally, we examined one HSV-2 HSE patient (patient #10) who experienced a genital herpes episode about 4.5 months after HSE (Table 2). To compare TK genotype variation in HSV isolates from concurrent or consecutive HSE and mucosal HSV infections, we sequenced the TK genes of HSV DNA obtained from multiple BLS and CSF samples of the same HSE patient (Table 2). TK sequences were identical for all sequential isolates of individual patients, including those from distinct anatomical HSV infection sites, suggesting potential involvement of the same HSV strain per time and anatomical site.

Because HSV isolates consist of mixtures of ACVS and ACVR variants [8–11], ACV therapy may select for ACVR variants; particularly in immunocompromised individuals and in immunoprivileged organs such as the eye and brain [8–11]. To determine the effect of ACV treatment on the appearance of ACVR HSV in HSE patients, we analyzed viral TK sequences in 3 consecutive CSF samples obtained from two HSE patients during ACV treatment (patients #3 and #9; Table 2). Whereas ACV treatment reduced intrathecal HSV DNA loads, emergence of ACVR-associated TK mutations in intrathecal HSV could not be detected (Tables 1 and 2). Likewise, we did not detect ACVR-associated mutations in HSV TK of CSF samples obtained at 4 and 40 days after onset of ACV therapy (patients #4 and #11, respectively). Thus, short-term ACV therapy did not select for detectable intrathecal ACVR-associated mutations in HSV TK in these 4 HSE patients.

Phenotypic ACV susceptibility of HSV isolates from HSE patients

Next we aimed to phenotypically characterize the ACV susceptibility of HSE isolates from HSE patients. HSV was isolated from BLS of oral HSV-1 and anal HSV-2 mucosal lesions (Tables 2 and 3), but could not be recovered from CSF due to the low viral loads and/or limited volume of residual sample. These findings are in accordance with the low success rate in recovering
culturable HSV from CSF samples (<4%) obtained from HSE patients [33, 34]. As outlined above, TK genotypes were identical in CSF and BLS samples from patients #3, #4, #10 and #11 (Table 2). HSV-1 isolates from patients #3 and #4, the latter containing the disputed R41H TK mutation, were not ACVR (Table 3). By contrast, HSV-2 BLS isolates from patient #10 and #11 obtained at 132 and 34 days after onset of ACV therapy were found to be ACVR in the absence of ACVR-associated TK mutations (Table 3 and Fig 1), suggesting involvement of additional mutations in the viral DNA polymerase gene.

Table 2. Viral thymidine kinase polymorphisms in clinical samples obtained from herpes simplex encephalitis patients.

| Patient | Virus | Clinical Sample | Time interval | Herpes simplex virus (HSV) thymidine kinase (TK) gene |
|---------|-------|----------------|---------------|----------------------------------------------------|
| Time interval (days) between the time point of first CSF sample and acquisition of the indicated sample. NA, not applicable. | | Virus load (gec/mL) | Nucleotide polymorphisms | Amino acid polymorphisms |
| | | | | Regular font: natural non-synonymous polymorphisms; Italics: natural synonymous polymorphisms; Bold: new mutation; Bold and underlined: mutation with unclear significance for ACV resistance. | |
| | | | | Predicted TK protein sequences were compared to reference HSV-1 TK (strain 17; GenBank accession number JN555585.1) and HSV-2 TK (strain HG52; NCBI accession number NC_001798.1) sequences. Regular font: natural polymorphisms; bold: new mutation; bold and underlined: mutation with unclear significance for ACV resistance. | |
| Pat 1 | HSV-1 | CSF | NA | NA | <5.0 x 10^3 | A106G, C171T, G266A, T271C, T717C, G793A, C892T, T933C and A1056C | K36E, R89Q and A265T |
| Pat 2 | HSV-1 | CSF | NA | 0 | 7.9 x 10^3 | A68G, G102A, A106G, C171T, G266A, T271C, C513T, C689T, T717C, G719A, G793A, T933C and G1056C | N23S, K36E, R89Q, A230V, G240E and A265T |
| Pat 3 | HSV-1 | CSF | NA | -2 | 1.3 x 10^6 | T16G, A68G, G102A, A106G, G122A, C171T, T271C, A528G, C575T, C672T, C513T, C689T, T717C, G723A, G751T, G793A, G799T, C802A, C858A, T915C, T933C, T953C and A1056C | K36E, R89Q and A265T |
| BLS | 2 | 0 | 1.4 x 10^4 | Identical to CSF1 | Identical to CSF1 |
| CSF2 | 3 | 1 | 3.5 x 10^3 | Identical to CSF1 | Identical to CSF1 |
| CSF3 | 10 | 8 | 4.4 x 10^4 | Identical to CSF1 | Identical to CSF1 |
| Pat 4 | HSV-1 | BLS1 | -4 | 0 | 8.0 x 10^6 | T16G, A24G, A68G, A106G, G116A, G39E, C171T, T271C, A528G, C575T, C672T, C513T, C689T, T717C, G723A, G751T, G793A, G799T, C802A, C858A, T915C, A230V, G240E and A265T, V267L, P268T, A265T, V267L, P268T, V267L and N376H | N23S, K36E, R41H, A192V, G251C, A265T, V267L, P268T, D286E and N376H |
| BLS2 | -1 | 3 | 3.8 x 10^7 | Identical to BLS1 | Identical to BLS1 |
| CSF | NA | 4 | 6.6 x 10^4 | Identical to BLS1 | Identical to BLS1 |
| Pat 5 | HSV-2 | CSF | NA | -2 | 2.2 x 10^6 | G116A | G39E |
| Pat 6 | HSV-2 | CSF | NA | 0 | 1.2 x 10^4 | G116A, A232G, G420T and C852T | G39E, N78D and L140F |
| Pat 7 | HSV-2 | CSF | NA | 0 | 1.0 x 10^3 | G116A | G39E |
| Pat 9 | HSV-2 | CSF1 | NA | 0 | 7.2 x 10^4 | G116A | G39E |
| CSF2 | 9 | 9 | 3.9 x 10^3 | Identical to CSF1 | Identical to CSF1 |
| Pat 10 | HSV-2 | CSF | NA | 0 | 2.1 x 10^5 | G116A | G39E |
| BLS | 132 | 132 | 1.3 x 10^5 | Identical to CSF | Identical to CSF |
| Pat 11 | HSV-2 | BLS | -6 | 34 | 1.9 x 10^7 | G116A and A752G | G39E and Q251R |
| CSF | NA | 40 | 5.9 x 10^3 | Identical to BLS | Identical to BLS |
| Pat 12 | HSV-2 | CSF | NA | 5 | 4.9 x 10^2 | G116A | G39E |

**a** Causative virus.  
**b** Sample type. CSF: cerebrospinal fluid; BLS: blister swab.  
**c** Time interval (days) between the time point of first CSF sample and acquisition of the indicated sample. NA, not applicable.  
**d** Time interval (days) between the start of antiviral (AV) treatment and the time of sampling. NA, not applicable. Values <0: sample obtained prior to onset AV therapy; Value = 0: AV therapy started on the day of sampling; Values >0: sample obtained after onset of AV therapy.  
**e** HSV genome equivalent copies per mL (gec/mL).  
**f** TK DNA sequences were compared to reference HSV-1 TK (strain 17; GenBank accession number JN555585.1) and HSV-2 TK (strain HG52; NCBI accession number NC_001798.1) sequences. Regular font: natural non-synonymous polymorphisms; Italics: natural synonymous polymorphisms; Bold: new mutation; Bold and underlined: mutation with unclear significance for ACV resistance.  
**g** Predicted TK protein sequences were compared to reference HSV-1 TK (strain 17; GenBank accession number JN555585.1) and HSV-2 TK (strain HG52; NCBI accession number NC_001798.1) sequences. Regular font: natural polymorphisms; bold: new mutation; bold and underlined: mutation with unclear significance for ACV resistance.  

**doi:** 10.1371/journal.pone.0155531.t002
Discussion

Preemptive intravenous ACV therapy has reduced morbidity and mortality in clinically suspected HSE patients [5–7]. Although ACV therapy refractory HSE case reports with intrathecal ACV HSV have been described [13–16], the prevalence of intrathecal ACV HSV-1 and HSV-2 in HSE patients is unknown. The current study showed that intrathecal ACV HSV-associated HSV TK mutations are uncommon in a cohort of clinically unbiased HSV-1 (n = 4) and HSV-2 (n = 8) HSE patients and do not appear to develop intrathecally.

Synonymous and non-synonymous mutations were detected in the HSV TK gene from 11 of 12 (92%) HSE patients, most of which were located outside the conserved regions of TK and have been described as natural polymorphisms [10–12, 23–27]. Patient #4 contained the D286E mutation located within the C-terminal conserved domain of HSV-1 TK (amino acid 284–289). This mutation was previously reported as natural polymorphism [10, 12, 23, 25, 26], which did not confer phenotypic ACV in the BLS HSV-1 isolate of patient #4, possibly because this mutation replaces the negatively charged amino acid aspartic acid with a similarly charged glutamic acid. CSF and BLS of patient #4 contained an HSV-1 isolate harboring the R41H TK mutation. This mutation has been identified in an intrathecal ACV HSV-1 isolate from an HSE patient refractory to ACV therapy [16] and we have previously shown that a recombinant HSV-1 TK protein containing R41H did not convert ACV to ACV-monophosphate in vitro [30]. By contrast, the R41H TK in the HSV-1 isolate from patient #4 did not confer ACV resistance (Table 3) corroborating previous reports describing this mutation as natural polymorphism [12,26,28]. The HSV-1 isolate from patient #2 contained a new mutation (A230V) located in the non-conserved region of HSV-1 TK (Fig 1) that is unlikely to affect TK function, although this needs to be experimentally verified in functional TK assays [18,35,36].

Consistent with previous studies our data indicate a higher prevalence of polymorphisms in the TK gene of HSV-1 compared to HSV-2 [12,21,37]. The genetic variability of the HSV-2

![Fig 1. Location of identified amino acid substitutions in HSV thymidine kinase.](image-url)

Schematic representation of all identified amino acid substitutions in the thymidine kinase (TK) proteins of intrathecal HSV-1 (A) and HSV-2 (B) isolates obtained from herpes simplex encephalitis patients. Note that except for the D286E mutation in HSV-1 all amino acid substitutions are located outside of the functional domains of TK. Grey boxes depict highly conserved and functional domains, i.e. ATP-binding site (ATP), nucleotide binding sites (NBS) and a cysteine residue at position 336 and 337 for HSV-1 and HSV-2, respectively [31, 32]. TK amino acid locations are indicated according to HSV-1 reference strain 17 (GenBank accession number: JN55585.1) and HSV-2 reference strain HG52 (NCBI accession number: NC_001798.1). Regular font: natural polymorphisms; bold: new mutation; bold and underlined: mutation with unclear significance for ACV resistance.

doi:10.1371/journal.pone.0155531.g001
The DNA polymerase gene exceeds that of the TK gene [38], suggesting a more prominent role of DNA polymerase mutations in the acquisition of ACVR in HSV-2 isolates. Notably, 2 HSV-2 BLS isolates obtained at 34 and 132 days after onset of ACV therapy from 2 immunocompromised patients (#10 and #11) were found to be phenotypically ACVR in the absence of known ACVR-associated TK mutations, suggestive of accompanying mutations in the viral DNA polymerase gene [12]. Alternatively, the isolate’s ACVR phenotype may be caused by G39E (patient #10) or G39E & Q251R (patient #11) HSV-2 TK polymorphisms in combination with mutations in genes encoding additional components of the viral DNA replication machinery: UL5, UL8, UL9, UL29, UL42 or UL52 [38, 39]. Interestingly, HSV ACVR did not affect clinical outcome in these 2 patients (Table 1). Overall, the data suggests that combined sequence analysis of viral TK and DNA polymerase genes is needed to determine the prevalence of ACVR in CSF samples of HSE patients in future studies.

Previous studies showed that ACV therapy was not associated with an increased risk for the emergence of ACVR HSV-1 in immunocompetent patients [40,41], supporting the currently recommended 14 to 21 days of intravenous ACV treatment of HSE patients [5,42]. The current study showed that HSV TK polymorphisms were present in CSF of 9 patients prior to the onset of ACV therapy. Furthermore, short-term ACV therapy (median: 8 days; range: 1–40 days) did not induce the emergence of ACVR-associated TK mutations in HSV isolates obtained from CSF samples of 4 HSE patients (Table 2). However, HSV clinical isolates are quasispecies composed of genetically related ACV-sensitive (ACVS) and ACV-resistant (ACVR) variants [10,21,43]. The relative abundance of ACVS and ACVR HSV determines the isolate’s susceptibility to ACV [10,43,44]. Due to limited quantities of HSV DNA recovered from rare CSF samples, we applied pool sequencing to determine the TK sequence of the major HSV isolate present in CSF or mucocutaneous samples. Whereas this reflects the responsiveness of HSE patients to ACV therapy, deep sequencing of HSV TK in future studies should provide more insight into the anticipated subtle emergence of intrathecal ACVR viruses in response to short-term ACV treatment of HSE patients.

### Table 3. Acyclovir susceptibility of HSV isolates obtained from mucocutaneous samples of herpes simplex encephalitis patients.

| Patient | Virus | Sample | Amino acid polymorphisms | Mean [± SD] IC50 of ACV (μM) | ACV susceptibility |
|---------|-------|--------|--------------------------|-----------------------------|-------------------|
| 3       | HSV-1 | BLS    | K36E, R89Q and A265T     | 0.34 [± 0.06]               | Sensitive         |
| 4       | HSV-1 | BLS1   | N23S, K36E, **R41H**, A192V, G251C, A265T, V267L, P268T, D286E and N376H | 3.50 [± 0.55] | Sensitive         |
|         |       | BLS2   | Identical to BLS1         | 2.85                        | Sensitive         |
| 10      | HSV-2 | BLS    | G39E                     | 14.27 [± 1.52]              | Resistant         |
| 11      | HSV-2 | BLS    | G39E and Q251R           | 20.17 [± 6.73]              | Resistant         |

* Causative virus.
* Sample type. BLS: blister swab.
* Predicted TK protein sequences were compared to ref HSV-1 TK (strain 17; GenBank accession number JN555585.1) and HSV-2 TK (strain HG52; NCBI accession number NC_001798.1) sequences. Regular font: natural polymorphisms; bold: new mutation; bold and underlined: mutation with unclear significance for ACV resistance.
* Mean half maximum (50%) inhibitory concentration (IC50) value of ACV ± standard deviation (SD) for the indicated isolates (n = 3 experiments). Mean IC50 value for the sensitive control strains HSV-1 F and HSV-2 HG52 were 1.11 μM and 1.93 μM, respectively.
* Isolates were designated as “Sensitive” or “Resistant” based on the ACV IC50 values. Cut-off value for ACV resistance was defined as ≥5 times the mean IC50 value of HSV-1 F strain (5.55 μM) and HSV-2 HG52 strain (9.65 μM).
* IC50 value represents mean of duplicate wells from a single experiment.

doi:10.1371/journal.pone.0155531.t003

DNA polymerase gene exceeds that of the TK gene [38], suggesting a more prominent role of DNA polymerase mutations in the acquisition of ACVR in HSV-2 isolates. Notably, 2 HSV-2 BLS isolates obtained at 34 and 132 days after onset of ACV therapy from 2 immunocompromised patients (#10 and #11) were found to be phenotypically ACVR in the absence of known ACVR-associated TK mutations, suggestive of accompanying mutations in the viral DNA polymerase gene [12]. Alternatively, the isolate’s ACVR phenotype may be caused by G39E (patient #10) or G39E & Q251R (patient #11) HSV-2 TK polymorphisms in combination with mutations in genes encoding additional components of the viral DNA replication machinery: UL5, UL8, UL9, UL29, UL42 or UL52 [38, 39]. Interestingly, HSV ACVR did not affect clinical outcome in these 2 patients (Table 1). Overall, the data suggests that combined sequence analysis of viral TK and DNA polymerase genes is needed to determine the prevalence of ACVR in CSF samples of HSE patients in future studies.

Previous studies showed that ACV therapy was not associated with an increased risk for the emergence of ACVR HSV-1 in immunocompetent patients [40,41], supporting the currently recommended 14 to 21 days of intravenous ACV treatment of HSE patients [5,42]. The current study showed that HSV TK polymorphisms were present in CSF of 9 patients prior to the onset of ACV therapy. Furthermore, short-term ACV therapy (median: 8 days; range: 1–40 days) did not induce the emergence of ACVR-associated TK mutations in HSV isolates obtained from CSF samples of 4 HSE patients (Table 2). However, HSV clinical isolates are quasispecies composed of genetically related ACV-sensitive (ACVS) and ACV-resistant (ACVR) variants [10,21,43]. The relative abundance of ACVS and ACVR HSV determines the isolate’s susceptibility to ACV [10,43,44]. Due to limited quantities of HSV DNA recovered from rare CSF samples, we applied pool sequencing to determine the TK sequence of the major HSV isolate present in CSF or mucocutaneous samples. Whereas this reflects the responsiveness of HSE patients to ACV therapy, deep sequencing of HSV TK in future studies should provide more insight into the anticipated subtle emergence of intrathecal ACVR viruses in response to short-term ACV treatment of HSE patients.
In addition to its role in ACVR, the genetic variability of the viral UL23 TK gene facilitates discrimination between HSV-1 strains [10,17,18,30]. We have shown that identical TK sequences were recovered from successive CSF samples and samples from distinct anatomical sites (i.e. CSF and BLS from herpetic oral or genital lesions), suggesting that consecutive HSE and mucosal HSV infections within the same individual could be caused by the same isolate. However, given the low genetic variability of HSV-2 TK, sequence analysis of HSV US4, US7 and US8 genes, commonly used to genotype HSV isolates [45, 46], in addition to TK sequencing in future studies may provide additional insight into the intra-individual HSV-1 and, especially, HSV-2 strain diversity.

In conclusion, we did not detect intrathecal ACVR-associated TK mutations in HSV isolates from HSE patients and short-term ACV therapy did not induce emergence of detectable ACVR-associated TK mutations. Given the low genetic variability in the TK gene of HSV-2 compared to HSV-1, combined sequence analysis of HSV TK and DNA polymerase genes is needed to conclusively determine the prevalence of ACVR HSV in HSE patients in future studies.

Acknowledgments

This work was supported by the Erasmus MC and by the Niedersachsen-Research Network on Neuroinfectiology from the Ministry of Science and Culture of Lower Saxony, Germany. The authors thank Freek B. van Loenen and Sarah Getu for technical assistance.

Author Contributions

Conceived and designed the experiments: JGM GPVN JJAVK GMGMV WJDO. Performed the experiments: JGM GPVN GIA. Analyzed the data: JGM GPVN JJAVK WJDO. Contributed reagents/materials/analysis tools: MJT. Wrote the paper: JGM MJT GPVN JJAVK ADMEO GMGMV WJDO.

References

1. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10:835–844. doi: 10.1016/S1473-3099(10)70222-X PMID: 20952256
2. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. Lancet 2002; 359:507–513 PMID: 11853816
3. Kennedy PGE, Steiner I. Recent issues in herpes simplex encephalitis. J Neurovirol 2013; 19:346–350. doi: 10.1007/s13365-013-0178-6 PMID: 23775137
4. Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? Curr Opin Neurol 2011; 24:268–274. doi: 10.1097/WCO.0b013e32834e2e6f PMID: 21482690
5. Gnann JW Jr, Sköldenberg B, Hart J, Aurelius E, Schlamser S, Studahl M, et al. Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy. Clin Infect Dis. 2015; 61:683–691. doi:10.1093/cid/civ369 PMID: 25956891
6. Sköldenberg B, Alestig K, Burman L, Forkman A, Lövgren K, Ragnar N, et al. Acyclovir versus vidarabine in herpes simplex encephalitis: randomized multicentre study in consecutive Swedish patients. Lancet 1984; 324:707–764.
7. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144–149. PMID: 3001520
8. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence and management. Antimicrob Agents Chemother 2011; 55:459–472. doi: 10.1128/AAC.00615-10 PMID: 21076929
9. Danve-Sztanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42:242–249. PMID: 14715760
10. Duan R, de Vries RD, van Dun JM, van Loenen FB, Osterhaus ADME, Remeijer L, et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009; 200:1402–1414. doi: 10.1086/606028 PMID: 19795980

11. Frobert E, Burrel S, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno JS, et al. Resistance of herpes simplex virus to acyclovir: from a ten-year survey in France. Antiviral Res 2014; 111:36–41. doi: 10.1016/j.antiviral.2014.08.013 PMID: 25218722

12. Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54:4833–4842. doi: 10.1128/AAC.00689-10 PMID: 20733037

13. Gateley A, Gander RM, Johnson PC, Kit S, Otsuka H, Kohl S. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 1990; 161:711–715. PMID: 21569461

14. Schepers K, Hernandez A, Andrei G, Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis 2013; 51:356–359. doi: 10.1093/cmi/myt017 PMID: 23100343

15. Nagamine M, Suzutani T, Saijo M, Hayashi K, Azuma M. Comparison of polymorphism of thymidine kinase gene and restriction fragment length polymorphism of genomic DNA in herpes simplex virus type 1. J Clin Microbiol 2000; 38:2750–2752. PMID: 10878078

16. Van Velzen M, van Loenen FB, Meesters RJ, de Graaf M, Remeijer L, Luider T, et al. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 2012; 205:1539–1543. doi: 10.1093/infdis/jis237 PMID: 22457282

17. FEDERA. Human tissue and medical research: Code of conduct for responsible use (2011). Available: https://www.federa.org/sites/default/files/digital_version_first_part_code_of_conduct_in_uk_2011_12092012.

18. Remeijer L, Duan R, van Dun JM, Wefers Bettink MA, Osterhaus AD, Verjans GM. Prevalence and clinical consequences of herpes simplex virus type 1 DNA in human cornea tissues. J Infect Dis 2009; 200:11–19. doi: 10.1086/599329 PMID: 19476433

19. Bohn K, Zell R, Schacke M, Wutzler P, Sauerbrei A. Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antivir Ther 2011; 16:989–997. doi: 10.3851/Imp1852 PMID: 22024514

20. Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54:4833–4842. doi: 10.1128/AAC.00689-10 PMID: 20733037

21. Bestman-Smith J, Schmit I, Papadopoulou B, Boivin G. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol 2001; 75:3105–3110. PMID: 11238837

22. Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet 1975; 305:480–484.

23. Andrei G, Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis 2013; 26:551–560. doi: 10.1097/QCO.000000000000015 PMID: 24152761

24. Bohn K, Zell R, Schacke M, Wutzler P, Sauerbrei A. Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antivir Ther 2011; 16:989–997. doi: 10.3851/Imp1852 PMID: 22024514

25. Schepers K, Hernandez A, Andrei G, Gillemot S, Fiten P, Opdenakker G, et al. Acyclovir-resistant herpes simplex virus encephalitis in a patient treated with anti-tumor necrosis factor-α monoclonal antibodies 2014; 59:67–70.

26. Schulte EC, Sauerbrei A, Hoffman D, Zimmer C, Hemmer B, Mühlau M. Acyclovir resistance in herpes simplex encephalitis. Ann Neurol 2010; 67:830–833. doi: 10.1002/ana.21979 PMID: 20517946

27. Andrei G, Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect DIS 2013; 26:551–560. doi: 10.1097/QCO.000000000000015 PMID: 24152761

28. Bestman-Smith J, Schmit I, Papadopoulou B, Boivin G. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol 2001; 75:3105–3110. PMID: 11238837

29. Sauerbrei A, Liermann K, Bohn K, Zell R, Gronowitz S, Wutzler P. Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antiviral Res 2012; 96:105–107. doi: 10.1016/j.antiviral.2012.08.001 PMID: 22906425
30. Van Velzen M, Misotten T, van Loenen FB, Meesters RJW, Luider TS, Baarsma GS, et al. Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients. J Clin Virol 2013; 57:215–221. doi:10.1016/j.jcv.2013.03.014 PMID: 23582986

31. Burrel S, Aime C, Hermet L, Ait-Arkoub Z, Agut H, Boutolleau D. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey. Antiviral Res 2013; 100:365–372. doi: 10.1016/j.antiviral.2013.09.012 PMID: 24075863

32. Graham DA, Larder BA, Inglis MM. Evidence that the ‘active centre’ of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J Gen Virol 1986; 67:753–758. PMID: 3007662

33. Nahmias AJ, Whitley RJ, Visintine AN, Takei Y, Alford CA Jr. Herpes simplex encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis 1982; 145:829–836. PMID: 6282983

34. Polage CR, Petti CA. Assessment of the utility of viral culture of cerebrospinal fluid. Clin Infect Dis. 2006; 15:1578–1579.

35. Malartre N, Bouilieu R, Falah N, Cortay JC, Lina B, Morfin F, et al. Effects of mutations on herpes simplex virus 1 thymidine kinase functionality: an in vitro assay based on detection of monophosphate forms of acyclovir and thymidine using HPLC/DAD. Antiviral Res 2012; 95:224–228. doi: 10.1016/j.antiviral.2012.07.001 PMID: 22796575

36. Sauerbrei A, Vödisch S, Bohn K, Schacke M, Gronowitz S. Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay. J Virol Methods 2013; 188:70–72. doi: 10.1016/j.jviromet.2012.12.001 PMID: 23246510

37. Chiba A, Suzutani M, Sijo S, Koyano S, Azuma M. Analysis of nucleotide sequence variations in herpes simplex viruses types 1 and 2, and varicella-zoster virus. Acta Virol 1998; 42:401–407. PMID: 10358747

38. Bohn-Wippert K, Schmidt S, Runzle A, Zell R, Sauerbrei A. Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades. Int J Med Microbiol 2015; 305:644–651. doi: 10.1016/j.ijmm.2015.08.014 PMID: 26338148

39. Matthews JT, Terry BJ, Kirk Field A. The structure and function of the HSV DNA replication proteins: defining novel antiviral targets. Antivir Res 1993; 20:89–114. PMID: 8384825

40. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boon GS. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir study group. J Infect Dis 1994; 169:1338–1341. PMID: 8195614

41. Sarisky RT, Bacon TH, Roon RJ, Duffy KE, Esser KM, Leary J, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 2003; 148:1757:1769. PMID: 14505088

42. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The management of encephalitis: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis 2008; 47:303–327. doi: 10.1086/589747 PMID: 18582201

43. Shin YK, Cai GY, Weinberg A, Leary JJ, Levin MJ. Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol 2001; 39:913–917. PMID: 11230403

44. Frobert E, Cortay JC, Ooka T, Najouilah F, Thouvenot D, Lina B, et al. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses. Antiviral Res 2008; 79:28–36. doi: 10.1016/j.antiviral.2008.01.153 PMID: 18336925

45. Norberg P, Bergström T, Rekabdar E, Lindh M, Liljegqvist JA. Phylogenetic analysis of clinical herpes simplex virus type 1 isolates identified three genetic groups and recombinant viruses. J Virol 2004; 78:10755–10764. PMID: 15367642

46. Norberg P, Kasubi MJ, Haar L, Bergström T, Liljegqvist JA. Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol 2007; 81:13158–13167. PMID: 17881457